ZIKAlliance Children Cohort (ZIKAllianceCH) (ZIKAllianceCH)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03393286|
Recruitment Status : Recruiting
First Posted : January 8, 2018
Last Update Posted : January 19, 2021
|Condition or disease|
The aim of this proposal is to evaluate the causal relationship between Zika virus (ZIKV) infections in pregnancy and congenital malformations. The study will estimate the absolute and relative risks of congenital malformations and other adverse outcomes of pregnancy among women who become infected with ZIKV during pregnancy compared to uninfected pregnant women, also leading to further validation of the Congenital Zika Syndrome.
The study will also determine the ZIKV maternal to child transmission rate and evaluate co-factors or effect modifiers that account for the large variability seen in the preliminary absolute risk estimates derived from population figures and reporting of microcephaly in different states in Brazil and across Latin America.
The study will carry out a pregnant women (PW) multicentre cohort study in areas across Latin America and the Caribbean. Women will be enrolled early in pregnancy and followed every 4 weeks, in connection with their routine antenatal care visits. At each visit, urine and blood samples will be collected, tested and stored.
Among PW reporting recent or current undifferentiated fever/rash syndrome at any point in time, the acute illness episode will be characterized in greater detail. PW with suspected ZIKV infection (i.e. meeting the Pan American Health Organization (PAHO) clinical case definition) during pregnancy will be managed according to national protocols. Irrespective of symptoms, pregnant women will be followed prospectively and revisited at birth (or after abortion) for a detailed documentation of the outcome of their pregnancy.
Live newborns will receive a detailed neonatal examination. In the course of examination of the newborns, biological samples will be collected and stored. Other potential causes of congenital abnormalities (TORCHS infections in the mother, toxic substances, chromosomal abnormalities), and potential effect modifiers (for example past flavivirus infections/vaccinations, socio-economic status) will also be assessed.
With appropriate counselling and consent, biological samples of newborns with severe abnormalities, deceased newborns, stillborn babies, and aborted foetuses from ZIKV-infected mothers will be collected to help elucidate the aetiological contribution of ZIKV in neurological and other congenital malformations.
Children of women infected with ZIKV during pregnancy - and a subset of the children born to uninfected women - will be followed prospectively after birth for the assessment of neuro-developmental milestones.
|Study Type :||Observational|
|Estimated Enrollment :||5000 participants|
|Official Title:||Children (CH) Cohort for the Evaluation of Developmental and Neurological Abnormalities in Infants Born to Mothers Residing in Areas With Zika Virus Transmission During Pregnancy|
|Actual Study Start Date :||January 15, 2018|
|Estimated Primary Completion Date :||September 30, 2021|
|Estimated Study Completion Date :||September 30, 2022|
- Congenital Abnormalities detected after birth as defined by the evolving definition of the congenital zika syndrome [ Time Frame: Birth ]
- Hearing abnormalities measured after birth [ Time Frame: Between birth and 2 years ]
- Visual abnormalities measured after birth [ Time Frame: Between birth and 2 years ]
- Developmental / cognitive abnormalities measured by the Ages and Stages 3rd Edition (ASQ3) [ Time Frame: Between birth and 2 years ]
- Developmental / cognitive abnormalities measured by the Bayley Scales of Infant and Toddler Development, Third Edition (BSID-III) [ Time Frame: 2 years ]
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03393286
|Contact: Thomas Jänisch||+49 6221 56 firstname.lastname@example.org|
|Sosecali Ltd. (SOSE)||Not yet recruiting|
|Contact: Carmen Soria|
|Contact: Eduardo Jurado|
|Fundacao Oswaldo Cruz (FIOCRUZ)||Not yet recruiting|
|Contact: Ernesto Marques email@example.com|
|Contact: Isabel Viana firstname.lastname@example.org|
|Fundacao Oswaldo Cruz (FIOCRUZ)||Not yet recruiting|
|Rio de Janeiro, Brazil|
|Contact: Patricia Brasil email@example.com|
|Contact: Renata Rabello firstname.lastname@example.org|
|University of Sao Paulo||Recruiting|
|São Paulo, Brazil|
|Contact: Vivian Avelino-Silva email@example.com|
|Contact: Aluisio Cotrim Segurado firstname.lastname@example.org|
|Industrial University of Santander (UIS)||Recruiting|
|Contact: Luis Villar|
|Contact: Maria Consuelo Miranda|
|Pedro Kouri Institute (IPK)||Not yet recruiting|
|Contact: Eric Martinez|
|Contact: Bruno Hoen|
|IMSS Mexico (IMSS)||Recruiting|
|Contact: Victor Hugo Borja-Aburto email@example.com|
|Contact: Cesar Gonzalez Cesar.firstname.lastname@example.org|
|National Institute of Public Health (INSP)||Recruiting|
|Contact: Hugo Lopez-Gatell email@example.com|
|Contact: Jennifer Hegewitsch firstname.lastname@example.org|
|Universidad de Carabobo / UMC Groningen (UMCG)||Recruiting|
|Contact: Adriana Tami-Grundmann email@example.com|
|Contact: Sarah Bethencourt|